It is believed that men diagnosed with prostate cancer and a low baseline serum testosterone (BST) may have more aggressive disease and it is frequently recommended they forego testosterone replacement therapy. We used two large phase III trials involving androgen deprivation therapy (ADT)…
Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials
To assess ultra-high (UH; PSA ≥ 50 ng/ml) patient outcomes compared to other high risk patients and to identify outcome predictors.
Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks)
Screening for prostate cancer remains a contentious issue. As with other cancer screening programs, a key feature of the debate is verification of cancer-specific mortality reductions. Unfortunately the present evidence, two systematic reviews and six randomized controlled trials, have reported conflicting results. Furthermore, half of…
Contemporary Analysis of Erectile, Voiding, and Oncologic Outcomes Following Primary Targeted Cryoablation of the Prostate for Clinically Localized Prostate Cancer
To evaluate erectile function (EF) and voiding function following primary targeted cryoablation of the prostate (TCAP) for clinically localized prostate cancer (CaP) in a contemporary cohort.
Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients’ clinical outcome
ETS (E26) fusions have been proposed to constitute a unique molecular subtype of prostate cancer (PCA), as evidenced by both their mutual exclusivity with other proposed PCA subtypes and the fundamentally different chromatin biology conferred by ETS-positivity [1–6]. These findings…
Event funds benefit Prostate Cancer Centre
